{"id":65090,"date":"2026-05-12T20:10:54","date_gmt":"2026-05-12T12:10:54","guid":{"rendered":"https:\/\/flcube.com\/?p=65090"},"modified":"2026-05-12T20:10:55","modified_gmt":"2026-05-12T12:10:55","slug":"ribo-life-science-files-ema-application-for-vortosiran-phase-iib-study-in-venous-thromboembolism-prevention","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65090","title":{"rendered":"Ribo Life Science Files EMA Application for Vortosiran Phase IIb Study in Venous Thromboembolism Prevention"},"content":{"rendered":"\n<p><strong>Suzhou Ribo Life Science Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6938:HKG\">HKG: 6938<\/a>) announced it has submitted a clinical trial application to the <strong>European Medicines Agency (EMA)<\/strong> to initiate a <strong>Phase IIb study<\/strong> evaluating <strong>vortosiran<\/strong>, its proprietary <strong>small interfering RNA (siRNA) drug targeting coagulation factor XI (FXI)<\/strong>, for the <strong>prevention and treatment of venous thromboembolism (VTE)<\/strong>. The novel anticoagulant aims to provide potent thromboembolism protection while significantly reducing bleeding risk compared to existing therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-development-update\">Regulatory Development Update<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Suzhou Ribo Life Science Co., Ltd. (HKG: 6938)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Vortosiran \u2013 siRNA targeting coagulation factor XI (FXI)<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Venous thromboembolism (VTE) prevention and treatment<\/td><\/tr><tr><td><strong>Regulatory Action<\/strong><\/td><td>EMA clinical trial application filed for Phase IIb study<\/td><\/tr><tr><td><strong>Recent Filings<\/strong><\/td><td>Phase IIb for atrial fibrillation (AF) filed last month<\/td><\/tr><tr><td><strong>Completed Studies<\/strong><\/td><td>Phase IIa for coronary artery disease (CAD) completed in EU<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-innovation\">Product Profile &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Platform:<\/strong> Small interfering RNA (siRNA) with extended duration of action<\/li>\n\n\n\n<li><strong>Target:<\/strong> Coagulation factor XI (FXI) \u2013 key mediator of pathological thrombosis<\/li>\n\n\n\n<li><strong>Mechanism Advantage:<\/strong> Blocks FXI-mediated coagulation pathway while preserving hemostatic function<\/li>\n\n\n\n<li><strong>Key Differentiator:<\/strong> Significantly reduced bleeding risk compared to conventional anticoagulants<\/li>\n\n\n\n<li><strong>Dosing Regimen:<\/strong> Likely subcutaneous administration with infrequent dosing due to siRNA durability<\/li>\n\n\n\n<li><strong>Therapeutic Rationale:<\/strong> Addresses fundamental limitation of current anticoagulants \u2013 bleeding complications<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance\">Strategic Significance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Anticoagulant Market Gap<\/strong><\/td><td>Current therapies (warfarin, DOACs) carry significant bleeding risks limiting their use<\/td><\/tr><tr><td><strong>Multi-Indication Strategy<\/strong><\/td><td>Simultaneous development across VTE, AF, and CAD demonstrates platform versatility<\/td><\/tr><tr><td><strong>European Focus<\/strong><\/td><td>Comprehensive EU clinical development program positions Ribo for global commercialization<\/td><\/tr><tr><td><strong>siRNA Leadership<\/strong><\/td><td>Validates Ribo&#8217;s position as China&#8217;s leading RNA therapeutics company<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The VTE filing represents the third major indication for vortosiran in cardiovascular thrombosis, creating a comprehensive development program across the spectrum of thrombotic diseases.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Anticoagulant Market:<\/strong> $25+ billion annual market with strong demand for safer alternatives<\/li>\n\n\n\n<li><strong>VTE Patient Population<\/strong> | Estimated 10 million annual cases globally with significant unmet needs in high-bleeding-risk patients<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong> | Multiple FXI inhibitors in development; Ribo&#8217;s siRNA approach offers potential dosing advantages<\/li>\n\n\n\n<li><strong>Commercial Potential<\/strong> | Peak sales projection of $1\u20132 billion globally if approved across multiple indications<\/li>\n\n\n\n<li><strong>Investment Implications<\/strong> | Success would validate siRNA platform for additional cardiovascular and rare disease targets<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory filings, clinical development plans, market opportunities, and commercial expectations for vortosiran. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051100616_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026051100616_c.\"><\/object><a id=\"wp-block-file--media-6f3da4a5-2b35-4852-a308-2618854c4c63\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051100616_c.pdf\">2026051100616_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051100616_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-6f3da4a5-2b35-4852-a308-2618854c4c63\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced it has submitted a clinical trial&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[90,4524,1725,64],"class_list":["post-65090","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-filings","tag-hkg-6938","tag-ribo-life-science","tag-rnai-aso"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ribo Life Science Files EMA Application for Vortosiran Phase IIb Study in Venous Thromboembolism Prevention - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced it has submitted a clinical trial application to the European Medicines Agency (EMA) to initiate a Phase IIb study evaluating vortosiran, its proprietary small interfering RNA (siRNA) drug targeting coagulation factor XI (FXI), for the prevention and treatment of venous thromboembolism (VTE). The novel anticoagulant aims to provide potent thromboembolism protection while significantly reducing bleeding risk compared to existing therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65090\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ribo Life Science Files EMA Application for Vortosiran Phase IIb Study in Venous Thromboembolism Prevention\" \/>\n<meta property=\"og:description\" content=\"Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced it has submitted a clinical trial application to the European Medicines Agency (EMA) to initiate a Phase IIb study evaluating vortosiran, its proprietary small interfering RNA (siRNA) drug targeting coagulation factor XI (FXI), for the prevention and treatment of venous thromboembolism (VTE). The novel anticoagulant aims to provide potent thromboembolism protection while significantly reducing bleeding risk compared to existing therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65090\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-12T12:10:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-12T12:10:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65090#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65090\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ribo Life Science Files EMA Application for Vortosiran Phase IIb Study in Venous Thromboembolism Prevention\",\"datePublished\":\"2026-05-12T12:10:54+00:00\",\"dateModified\":\"2026-05-12T12:10:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65090\"},\"wordCount\":411,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial filings\",\"HKG: 6938\",\"Ribo Life Science\",\"RNAi \\\/ ASO\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65090#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65090\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65090\",\"name\":\"Ribo Life Science Files EMA Application for Vortosiran Phase IIb Study in Venous Thromboembolism Prevention - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-12T12:10:54+00:00\",\"dateModified\":\"2026-05-12T12:10:55+00:00\",\"description\":\"Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced it has submitted a clinical trial application to the European Medicines Agency (EMA) to initiate a Phase IIb study evaluating vortosiran, its proprietary small interfering RNA (siRNA) drug targeting coagulation factor XI (FXI), for the prevention and treatment of venous thromboembolism (VTE). The novel anticoagulant aims to provide potent thromboembolism protection while significantly reducing bleeding risk compared to existing therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65090#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65090\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65090#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ribo Life Science Files EMA Application for Vortosiran Phase IIb Study in Venous Thromboembolism Prevention\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ribo Life Science Files EMA Application for Vortosiran Phase IIb Study in Venous Thromboembolism Prevention - Insight, China&#039;s Pharmaceutical Industry","description":"Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced it has submitted a clinical trial application to the European Medicines Agency (EMA) to initiate a Phase IIb study evaluating vortosiran, its proprietary small interfering RNA (siRNA) drug targeting coagulation factor XI (FXI), for the prevention and treatment of venous thromboembolism (VTE). The novel anticoagulant aims to provide potent thromboembolism protection while significantly reducing bleeding risk compared to existing therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65090","og_locale":"en_US","og_type":"article","og_title":"Ribo Life Science Files EMA Application for Vortosiran Phase IIb Study in Venous Thromboembolism Prevention","og_description":"Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced it has submitted a clinical trial application to the European Medicines Agency (EMA) to initiate a Phase IIb study evaluating vortosiran, its proprietary small interfering RNA (siRNA) drug targeting coagulation factor XI (FXI), for the prevention and treatment of venous thromboembolism (VTE). The novel anticoagulant aims to provide potent thromboembolism protection while significantly reducing bleeding risk compared to existing therapies.","og_url":"https:\/\/flcube.com\/?p=65090","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-12T12:10:54+00:00","article_modified_time":"2026-05-12T12:10:55+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65090#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65090"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ribo Life Science Files EMA Application for Vortosiran Phase IIb Study in Venous Thromboembolism Prevention","datePublished":"2026-05-12T12:10:54+00:00","dateModified":"2026-05-12T12:10:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65090"},"wordCount":411,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial filings","HKG: 6938","Ribo Life Science","RNAi \/ ASO"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65090#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65090","url":"https:\/\/flcube.com\/?p=65090","name":"Ribo Life Science Files EMA Application for Vortosiran Phase IIb Study in Venous Thromboembolism Prevention - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-12T12:10:54+00:00","dateModified":"2026-05-12T12:10:55+00:00","description":"Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced it has submitted a clinical trial application to the European Medicines Agency (EMA) to initiate a Phase IIb study evaluating vortosiran, its proprietary small interfering RNA (siRNA) drug targeting coagulation factor XI (FXI), for the prevention and treatment of venous thromboembolism (VTE). The novel anticoagulant aims to provide potent thromboembolism protection while significantly reducing bleeding risk compared to existing therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65090#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65090"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65090#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ribo Life Science Files EMA Application for Vortosiran Phase IIb Study in Venous Thromboembolism Prevention"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65090"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65090\/revisions"}],"predecessor-version":[{"id":65092,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65090\/revisions\/65092"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65090"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65090"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}